Immutep Ltd (NAS:IMMP)

$ 3.1 0.14 (4.73%) Market Cap: 368.53 Mil Enterprise Value: 300.07 Mil PE Ratio: 0 PB Ratio: 4.77 GF Score: 41/100

Immutep Ltd Annual Shareholders Meeting Transcript
Oct 23, 2023
Immutep Ltd ShareCafe Hidden Gems Webinar Transcript
Jun 26, 2023
Immutep Ltd at Jefferies Healthcare Conference Transcript
Jun 08, 2023
KOL Event hosted by Ladenburg Thalmann & Co, Inc. Transcript
May 09, 2023
Immutep Ltd at Jefferies London Healthcare Conference Transcript
Nov 17, 2022
Immutep Ltd at Ladenburg Thalmann Healthcare Conference Transcript
Sep 29, 2022
Immutep Ltd Annual Shareholders Meeting Transcript
Nov 25, 2021
Immutep Ltd at ASX Small & Mid-Cap Virtual Conference Transcript
Sep 08, 2020
Immutep CEO presentation BIO Asia-Taiwan Transcript
Jul 09, 2020
Immutep TACTI-002 and INSIGHT Global Webcast Slides Transcript
Jun 02, 2020
Immutep Ltd at NWR Communications Virtual Health Conference Transcript
May 04, 2020
Immutep Ltd Call For Topline Data From The Phase IIb AIPAC Study In HER2-negative/HR+ Metastatic Breast Cancer Transcript
Mar 25, 2020
Immutep Ltd TACTI-002 Clinical Results & Update Global Webcast Transcript
Feb 25, 2020
Immutep Ltd Eftilagimod Alpha Clinical Development Update And New Data From Ongoing Melanoma Study Transcript
Apr 02, 2019
Immutep Ltd IMP761 Preclinical Results In Global Webcast Transcript
Mar 25, 2019

Immutep Ltd Eftilagimod Alpha Clinical Development Update And New Data From Ongoing Melanoma Study Transcript

Apr 02, 2019 / 08:45PM GMT

Release Date Price: $2.16

Transcript

Clive Tompkins

Okay. Good morning, everyone. Thank you for joining us for another Immutep Investor Call to discuss on the company's lead candidate, eftilagimod alpha. I'm Clive Tomkins here in Sydney. I'll be your moderator today. (Operator Instructions)

I'd now like to hand you over to Marc Voigt, Immutep's CEO, to start the presentation. Over to you, Marc.

Marc Voigt

Immutep Limited - CEO, CFO, Chief Business Officer & Executive Director

Thank you, Clive, and welcome, everyone. We very much appreciate your time on the call today. Our forward-looking statement: We're very pleased to give you an update on our clinical development strategy for our lead product candidate, eftilagimod alpha, also known as efti or IMP321 as well as presenting data from our ongoing melanoma study called TACTI-mel and new updates on our other studies. On the call with me today, we have Professor FrÃ©dÃ©ric Triebel, who is our CMO and CSO; along with Christian Mueller, our Director Clinical Development and Regulatory Affairs.

Before we dive into the slides, I would

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.